专业监测看板

Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant

药物 / 成分：Degarelix、Gemcitabine/Cisplatin

登记的停止原因（原文）：Principal Investigator left institution

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

药物 / 成分：TRX-221

登记的停止原因（原文）：Sponsor's decision

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

药物 / 成分：AMG 378、Placebo

登记的停止原因（原文）：Business Decision

Open-label Extension Study of Brazikumab in Crohn's Disease

药物 / 成分：Brazikumab Induction Dose、Brazikumab Maintenance Dose

登记的停止原因（原文）：Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

药物 / 成分：VAY736、lenalidomide

登记的停止原因（原文）：Business decision and not due to any safety or tolerability concerns.

A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain

药物 / 成分：Multimodal Bundle Drugs、Operative Cystoscopy、Behavioral health consultation/therapy、Pelvic floor physical therapy

登记的停止原因（原文）：unable to reach the recruitment numbers required to power our primary outcome

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

药物 / 成分：Kamuvudine-9、Kamuvudine-9

登记的停止原因（原文）：Low enrollment status

A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood

药物 / 成分：BI 3009947 (Formulation A)、BI 3009947 (Formulation B)、Placebo

登记的停止原因（原文）：Sponsor decision

Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion

药物 / 成分：Idarubicin and Lipiodol

登记的停止原因（原文）：Enrollement rythm low, funding body decision.

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

药物 / 成分：Vatiquinone、Placebo

登记的停止原因（原文）：Sponsor decision.

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

药物 / 成分：Abemaciclib、Elacestrant

登记的停止原因（原文）：Study was terminated due to delayed recruitment.

A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets

药物 / 成分：TQB3720

登记的停止原因（原文）：Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

药物 / 成分：Lorecivivint

登记的停止原因（原文）：Study was terminated by Sponsor based on a business decision not due to safety. The study report was finalized without any statistical analysis.

A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA

药物 / 成分：QUC398、Placebo

登记的停止原因（原文）：Sponsor Decision

Spesolimab in Pyoderma Gangrenosum

药物 / 成分：Spesolimab

登记的停止原因（原文）：The funding sponsor terminated our study and will conduct a multicenter national study in its place.

Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer

药物 / 成分：Xevinapant、Carboplatin、Paclitaxel、Radiation Therapy

登记的停止原因（原文）：Drug no longer being developed by manufacturer

Safety of Bryostatin in Patients With MS

药物 / 成分：Bryostatin 1

登记的停止原因（原文）：Sponsor terminated funding.

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

药物 / 成分：OMS721 (narsoplimab)

登记的停止原因（原文）：Study terminated by Sponsor

Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)

药物 / 成分：Depletion in CD45RA graft donor

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

药物 / 成分：CDZ173

登记的停止原因（原文）：All participant have transitioned to commercial product or compassionate use.